Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805542 | 0.88 | USP1 (0.46) | CYP1A2CYP3A4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL801894 | 0.79 | EGFR (0.41) | EGFRCYP1A2CYP3A4HSD17B10CLK4 | |
| SCHEMBL801502 | 0.77 | AURKA (0.50) | CYP1A2CYP3A4HSD17B10CLK4ALDH1A1 | |
| SCHEMBL802046 | 0.77 | PRKD3 (0.41) | EGFRCYP1A2CYP3A4HSD17B10CLK4 | |
| SCHEMBL802375 | 0.75 | ALDH1A1 (0.42) | EGFRCYP1A2CYP3A4HSD17B10CLK4 | |
| SCHEMBL802515 | 0.75 | MAPT (0.49) | CYP1A2CYP3A4HSD17B10CLK4ALDH1A1 | |
| SCHEMBL801542 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP3A4HSD17B10CLK4ALDH1A1 | |
| SCHEMBL785995 | 0.74 | CYP1A2 (0.53) | CYP1A2CYP3A4HSD17B10CLK4ALDH1A1 | |
| SCHEMBL786263 | 0.74 | MAPT (0.48) | CYP1A2CYP3A4HSD17B10CLK4ALDH1A1 | |
| SCHEMBL802123 | 0.74 | MEN1 (0.57) | EGFRLMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7390815-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | EGFR 154/4885CYP1A2 3042/4885CYP3A4 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.